|
|
 Acceleron to Present at the Cowen and Company 29th Annual Health Care ConferenceCAMBRIDGE, Mass. – March 12, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron will provide a corporate presentation at the Cowen and Company 29th Annual Health Care Conference on Monday, March 16, 2009 at 9:30 AM (EDT). The conference will be held at the Boston Marriott Copley Place Hotel in Boston, MA. About Acceleron Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, red blood cells, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the Growth and Differentiation Factor (GDF) family of proteins. ACE-011 is currently being studied in a Phase 2 clinical trial in multiple myeloma patients with osteolytic bone disease. ACE-031 is currently being studied in a Phase 1 clinical trial in healthy volunteers. In addition, the company is advancing new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase hemoglobin. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Bessemer Ventures, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com. CONTACT: Paul Kidwell (Media) |
| Home|Privacy Policy|Site Map|Website design by Garfield Group | © 2009 Acceleron Pharma. All rights reserved. |